You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Bremelanotide acetate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for bremelanotide acetate and what is the scope of freedom to operate?

Bremelanotide acetate is the generic ingredient in one branded drug marketed by Palatin Technologies and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bremelanotide acetate has eighty patent family members in twenty-six countries.

One supplier is listed for this compound.

Summary for bremelanotide acetate
International Patents:80
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 1
DailyMed Link:bremelanotide acetate at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bremelanotide acetate
Generic Entry Date for bremelanotide acetate*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for bremelanotide acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Palatin Technologies, IncPhase 2

See all bremelanotide acetate clinical trials

Pharmacology for bremelanotide acetate

US Patents and Regulatory Information for bremelanotide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Palatin Technologies VYLEESI (AUTOINJECTOR) bremelanotide acetate SOLUTION;SUBCUTANEOUS 210557-001 Jun 21, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for bremelanotide acetate

Country Patent Number Title Estimated Expiration
Singapore 11201502949Q BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION ⤷  Try a Trial
Hong Kong 1211227 用於女性性功能障礙的佈雷默浪丹療法 (BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION) ⤷  Try a Trial
Japan 2008500369 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 2005117935 ⤷  Try a Trial
Malaysia 179755 USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.